A Daily Network publication
Explore the network
Private Wealth Daily
Independent Intelligence on the Private Wealth Industry
Friday, October 2, 2026The Morning Brief →Sign in
IBBISharesINDEX

iShares Biotechnology ETF

$205.96-2.17% vs prior close
14921752-WK

Price through Oct 1 · Flows through Sep 30. Figures use the latest available records, not a live quote. Fund details retrieved Oct 1. Holdings snapshot retrieved Oct 1.

The fund generally will invest at least 80% of its assets in the component securities of its index and in investments that have economic characteristics that are substantially identical to the component securities of its index and may invest up to 20% of its assets in certain futures, options and swap contracts, cash and cash equivalents. It is non-diversified.

Price & daily flows
202.2182.7163.2205.96DAILY NET FLOWOct 1Jan 30Jun 1Oct 1

SOURCE: MARKET TAPE & DAILY CREATION/REDEMPTION RECORDS · 1Y SHOWN · NET +$2.2B OVER THIS RANGE

The desk’s read

Money keeps arriving — +$656M of net inflows over the past month, about 6.1% of the fund's asset base, while the price has returned +22.0% so far this year. At 0.45% a year it is not the cheapest way in — FDHT has a reported fee of 0.39%.

COMPOSED FROM THE FUND’S OWN DAILY RECORDS · UPDATED WITH EACH REFRESH

$10.7Bassets under management
0.45%expense ratio · $45 per $10,000 a year
+$656Mnet flow, trailing month
1.5Mavg daily volume, 30 days
221holdings · US-domiciled
2001listed February 5, 2001 · beta 0.78
The book at a glance
GILD-1.5%AMGN-0.5%VRTX-0.7%REGN+1.0%MRNA-5.4%NTRA-0.3%ARGX-1.2%ILMN+0.6%RVMD+0.4%BIIB-0.5%ALNY-2.9%ONC+0.2%INSM-1.3%INCY-1.5%UTHR+12.5%GMAB+0.3%ROIV+0.2%NBIX+2.5%ASND-0.1%MEDP+0.3%EXEL-0.4%CRL-0.3%HALO-1.0%TWST+3.8%BBIO-0.3%BMRN+0.2%TECH+0.1%MDGL-1.1%TXG+0.4%RGENBNTX

CELL SIZE IS PORTFOLIO WEIGHT · COLOR IS THE CHANGE IN THE LATEST AVAILABLE SNAPSHOT · TOP 40 POSITIONS

HoldingsDownload CSV
#HoldingWeightPriceDay52-wk
1GILDGILEAD SCIENCES8.18%$149.05-1.5%
2AMGNAMGEN7.80%$421.51-0.5%
3VRTXVERTEX PHARMACEUTICALS7.65%$522.81-0.7%
4REGNREGENERON PHARMACEUTICALS5.21%$758.27+1.0%
5MRNAMODERNA5.20%$192.57-5.4%
6NTRANATERA3.91%$413.31-0.3%
7ARGXARGENX SE3.78%$958.91-1.2%
8ILMNILLUMINA2.87%$273.68+0.6%
9RVMDREVOLUTION MEDICINES2.76%$205.26+0.4%
10BIIBBIOGEN2.33%$225.88-0.5%
11ALNYALNYLAM PHARMACEUTICALS2.37%$246.74-2.9%
12ONCBeiGene2.15%$365.94+0.2%
13INSMINSMED1.74%$114.14-1.3%
14INCYINCYTE1.73%$121.35-1.5%
15UTHRUNITED THERAPEUTICS1.40%$541.89+12.5%

The full book, free with one sign-in.

Top 15 positions are open to everyone. Sign in once and every fund’s complete holdings — plus CSV export, watchlists, and flow alerts — unlock across the network.

Sign in to see all 221
Sector weights
Health Care99.81%
Cash and/or Derivatives0.15%
PORTFOLIO COMPOSITION, LATEST DISCLOSURE
Country weights
United States89.97%
Belgium3.87%
China2.55%
Denmark1.38%
Germany0.66%
France0.5%
Canada0.26%
United Kingdom0.26%
PORTFOLIO COMPOSITION, LATEST DISCLOSURE
Performance
1 week-1.8%
1 month-2.3%
3 months+8.3%
6 months+27.2%
YTD+22.0%
1 year+38.7%
3 years—

PRICE RETURN, DISTRIBUTIONS NOT REINVESTED

Net flows
1 week+$454M
1 month+$656M
3 months+$1.4B
YTD+$864M
1 year+$2.2B

CREATION/REDEMPTION DOLLARS, DAILY RECORDS

Monthly net flows
SepOctNovDecJanFebMarAprMayJulAugSep
DAILY CREATION/REDEMPTION RECORDS, TRAILING TWELVE MONTHS
The risk read
21%realized volatility, 30 days (annualized)
22%realized volatility, 1 year
-9.7%deepest fall from a peak, 1 year
-5.1%latest close versus that peak

The top holding is 8.2% of the book; the top ten carry 50%. Spread across 229+ names, it behaves like roughly 30 equally-weighted positions.

VOLATILITY & DRAWDOWN FROM THE DAILY TAPE · CONCENTRATION FROM THE LATEST DISCLOSED BOOK

Options tape
150calls · latest snapshot
136puts · latest snapshot
0.91put/call ratio
1.9Mshares traded
Most-traded holdings, options premiumBullishBearish
MRNA MODERNA$36M$41M
PRAX PRAXIS PRECISION MEDICINES$6M$3M
AMGN AMGEN$4M$4M
IOVA IOVANCE BIOTHERAPEUTICS$4M$4M
TEM TEMPUS AI INC$3M$4M

TODAY’S OPTIONS PREMIUM IN THE FUND’S UNDERLYING NAMES

The case against IBB

Due diligence cuts both ways. These funds sit on the same shelf and beat IBB on at least one dimension that matters — the fee, the asset base, or where the money is going.

FundFeeAssetsFlow, 1MThe case
SPDW State Street SPDR Portfolio Developed World ex-US ETF0.03%$41.5B+$286M-42bp on fee · 4× the assets · +$286M in over the monthHead-to-head
BBUS JPMorgan BetaBuilders U.S. Equity ETF0.02%$9.4B+$187M-43bp on fee · +$187M in over the monthHead-to-head
SPMD State Street SPDR Portfolio S&P 400 Mid Cap ETF0.03%$18.2B+$199M-42bp on fee · 2× the assets · +$199M in over the monthHead-to-head
SPYG State Street SPDR Portfolio S&P 500 Growth ETF0.04%$56.2B+$717M-41bp on fee · 5× the assets · +$717M in over the monthHead-to-head
SPTM State Street SPDR Portfolio S&P 1500 Composite Stock Market ETF0.03%$14.1B+$235M-42bp on fee · +$235M in over the monthHead-to-head
Sign in to save this to The RecordA timestamped copy for the file — documentation, not advice.
InstrumentsHarvest substitutesTrade cost at $1MClient tearsheetStress this fund
Every weekday · 6:30 a.m. ET

The Morning Brief

The private wealth industry in four minutes, every weekday at 6:30 a.m. ET. Free.